Europe Lymphangioleiomyomatosis Lam Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2021 –2028 |
 Taille du marché (année de référence) |
USD 33.98 Million |
 Taille du marché (année de prévision) |
USD 45.85 Million |
 TCAC |
% |
| Principaux acteurs du marché |
Marché européen de la lymphangioléiomyomatose (LAM), par type de maladie (sclérose tubéreuse complexe Lam, Lam sporadique et autres), par type (diagnostic, traitement), par complications (pneumothorax, chylothorax, tumeur rénale, épanchements pleuraux , gonflement et accumulation de liquide, autres), par voie d'administration (orale, parentérale, autres), par utilisateur final (hôpitaux, cliniques spécialisées, centres de diagnostic, soins à domicile et autres), par canal de distribution (appel d'offres direct, pharmacies hospitalières, pharmacies de détail, pharmacies en ligne, autres) Pays (Allemagne, France, Italie, Royaume-Uni, Espagne, Pays-Bas, Russie, Suisse, Turquie, Belgique, reste de l'Europe) Tendances et prévisions de l'industrie jusqu'en 2028.
Analyse et perspectives du marché : marché européen de la lymphangioléiomyomatose (LAM)
Le marché européen de la lymphangioléiomyomatose (LAM) devrait connaître une croissance de marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 4,1 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 45,85 millions USD d'ici 2028 contre 33,98 millions USD en 2020. L'incidence croissante du diabète et la croissance des nouvelles avancées technologiques pour la lymphangioléiomyomatose (LAM) sont susceptibles d'être les principaux moteurs qui propulsent la demande du marché au cours de la période de prévision.
La lymphangioléiomyomatose (LAM) est une maladie pulmonaire chronique kystique rare qui affecte le système pulmonaire, le système rénal et le système lymphatique. Le système lymphatique est constitué d'un réseau coordonné de vaisseaux, qui est responsable du transport du liquide lymphatique et des cellules immunitaires dans tout le corps. La LAM survient chez la population féminine. Les femmes âgées de 20 à 40 ans reçoivent un diagnostic de LAM. Environ 30 % des femmes atteintes de sclérose tubéreuse sont sujettes à la LAM. Elle survient souvent en raison de la mutation du complexe de sclérose tubéreuse (TSC), gène TSC 1. La LAM isolée ou sporadique fait référence à l'apparition de la LAM seule.
La lymphangiogéliomyomatose est due à des mutations dans les deux gènes respectifs, TSC 1 et TSC 2. La première forme de mutation est héréditaire et survient chez les patients atteints de sclérose tubéreuse. La deuxième forme n'est pas liée à la sclérose tubéreuse, elle est appelée LAM sporadique. Les personnes atteintes de LAM sporadique présentent également des mutations génétiques, mais ces mutations génétiques ne sont pas héréditaires et ne peuvent pas être transmises aux enfants. La raison pour laquelle ces mutations génétiques se produisent n'est pas claire.
L'augmentation de la prévalence des maladies pulmonaires kystiques chroniques, l'augmentation de l'angiomyolipome et de la sclérose tubéreuse chez les femmes et l'augmentation des essais cliniques ouvrent la voie à la croissance du marché de la lymphangioléiomyomatose (LAM). De plus, le potentiel de croissance des économies émergentes pour la lymphangioléiomyomatose (LAM) et l'augmentation des produits (machines de diagnostic et médicaments génériques) soutiennent la croissance du marché de la lymphangioléiomyomatose (LAM). Cependant, l'augmentation du coût du traitement de la LAM, les réglementations strictes imposées et l'inaccessibilité de la lymphangioléiomyomatose (LAM) aux pays en développement sont les contraintes qui peuvent entraver la croissance du marché. Les incohérences dans le matériel utilisé sont les contraintes qui peuvent entraver la croissance du marché.
Le rapport sur le marché européen de la lymphangioléiomyomatose (LAM) fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un dossier d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché de la lymphangioléiomyomatose (LAM) en Europe
Le marché européen de la lymphangioléiomyomatose (LAM) est segmenté en fonction du type de maladie, du type, des complications, de la voie d'administration, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base du type de maladie, le marché européen de la lymphangioléiomyomatose (LAM) est segmenté en complexe de sclérose tubéreuse lam et lam sporadique. En 2021, le segment complexe de la sclérose tubéreuse lam domine le marché européen de la lymphangioléiomyomatose (LAM) en raison de l'augmentation de l'angiomyolipome dans la population féminine en Europe qui devrait dominer le marché.
- On the basis of type, the Europe lymphangioleiomyomatosis (LAM ) market is segmented into diagnosis and treatment. The diagnosis segment is further segmented into blood test (vascular endothelial growth factor d (vegf-d)) and imaging test, lung function test, lung biopsy test, and others. The imaging test is further sub segmented into chest x-rays, chest CT scans, MRI of abdomen and others. The lung biopsy test is further sub-segmented into transbronchial lung biopsy and video-assisted thorascopic lung biopsy. The treatment segment is further segmented into medication, oxygen therapy, and lung transplantation. The medication is further sub-segmented into mtor inhibitors and bronchodilators. The mTOR inhibitors are further sub-segmented into sirolimus/ rapamycin, everolimus and others. The bronchodilators are further sub-segmented into albuterol, formoterol, salmeterol and others. The lung transplantation is further sub-segmented into single-lung transplantation (SLT) and bilateral lung transplantation (BLT). In 2021 the treatment segment is dominating theEuropelymphangioleiomyomatosis (LAM) market owing to the rise in the number of cases and availability of generics, diagnostic and lung transplants.
- On the basis of complications, the Europe lymphangioleiomyomatosis (LAM) market is segmented into pneumothorax, chylothorax, kidney tumor, pleural effusions, swelling & fluid build-up, and others. In 2021, the pneumothorax segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the increased prevalence of female patients suffering from the pulmonary disorder and timely diagnosis and treatment are predicted to dominate the market.
- On the basis of route of administration, the Europe lymphangioleiomyomatosis (LAM) market is segmented into oral, parenteral. The oral segment is further segmented into tablets, capsules, and others. The parenteral segment is further segmented into intravenous subcutaneous and others. In 2021, the oral segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the ease of absorption, and availability of oral medications in Europe are predicted to dominate the market.
- On the basis of end user, theEurope lymphangioleiomyomatosis (LAM) market is segmented into hospitals, specialty clinics, diagnostic centers, home healthcare and others. In 2021, the hospitals segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the increased need for treatment of lymphangioleiomyomatosis and the improvement in healthcare infrastructure in Europe are predicted to dominate the market.
- On the basis of distribution channel, the Europelymphangioleiomyomatosis (LAM) market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2021, the direct tender segment is expected to dominate theEuropelymphangioleiomyomatosis (LAM) market due to the rise in access to sirolimus medications, the surge in the number of prescriptions daily and the rise in the number of contacts for the distribution of diagnostic medications and bronchodilators are predicted to dominate the market.
Europe Lymphangioleiomyomatosis (LAM) Market Country Level Analysis
The Europe lymphangioleiomyomatosis (LAM) market is analysed and market size information is provided by product & services, sample type, process, application, compound library size, end user, and distribution channel.
The countries covered in the Europe lymphangioleiomyomatosis (LAM)market report are the Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Turkey & rest of Europe.
Europe is expected to grow with the CAGR in the forecasted periods as in the growing R&D activities in the pharma and biotech sector. Germany is expected to dominate in the market in the Europe market. Germany is one of the leading countries due to the presence of major market players and increased technological advancement in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
The Growth Potential for Lymphangioleiomyomatosis (LAM)in Emerging Economies and the Strategic Initiatives by Market Players are creating new Opportunities in the Europe Lymphangioleiomyomatosis (LAM) Market
Europe lymphangioleiomyomatosis (LAM) market also provides you with detailed market analysis for every country growth in particular industry with lymphangioleiomyomatosis (LAM)sales, impact of advancement in the lymphangioleiomyomatosis (LAM), and changes in regulatory scenarios with their support for the lymphangioleiomyomatosis (LAM)market. The data is available for historic period 2019 to 2028.
Competitive Landscape and Europe Lymphangioleiomyomatosis (LAM) Market Share Analysis
Le paysage concurrentiel du marché européen de la lymphangioléiomyomatose (LAM) fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et la portée du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise liée au marché de la lymphangioléiomyomatose (LAM).
Les principales sociétés fournissant le traitement de la lymphangioléiomyomatose (LAM) en Europe sont Pfizer Inc, Intas Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Dr. Reddy's Laboratories Ltd, Novartis AG, Hikma Pharmaceuticals PLC, TransMedics Group, Inc, Terumo Corporation, HERSILL, Care Dx, XVIVO, Taj Pharmaceuticals Limited
Les initiatives stratégiques des acteurs du marché, ainsi que les nouvelles avancées technologiques pour la lymphangioléiomyomatose (LAM), comblent le fossé dans le traitement des plaies chroniques.
Par exemple,
- En janvier 2020, Amneal Pharmaceuticals LLC a émis un avertissement auprès de la Food and Drug Administration (FDA) concernant l'utilisation d'un auto-injecteur d'épinéphrine, utilisé par Impax Laboratories, LLC, une filiale d'Amneal Pharmaceuticals. L'avertissement indiquait que l'appareil avait le potentiel d'administrer une double dose au patient. Ce concept peut nuire à la santé du patient souffrant de sclérose tubéreuse complexe LAM et peut entraver la production des auto-injecteurs d'épinéphrine.
La collaboration, les coentreprises et d'autres stratégies des acteurs du marché améliorent le marché de l'entreprise sur le marché européen de la lymphangioléiomyomatose (LAM), ce qui offre également l'avantage à l'organisation d'améliorer son offre de produits de traitement.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET INDICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 EUROPE LYMPHANGIOLEIOMYOMATOSIS MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN PREVALENCE OF CHRONIC CYSTIC LUNG DISORDERS
7.1.2 RISE OF ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) IN WOMEN
7.1.3 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 HEALTHCAREREIMBURSEMENTFOR LYMPHANGIOLEIOMYOMATOSIS
7.2 RESTRAINTS
7.2.1 RISE IN COST FOR LYMPHANGIOLEIOMYOMATOSIS (LAM) TREATMENT
7.2.2 AVAILABILITY OF ALTERNATIVES
7.2.3 HIGH COMPLEXITY IN LAM
7.2.4 STRICT REGULATORY FRAMEWORK
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE
7.3.2 RISE IN PRODUCT APPROVALS
7.3.3 USE OF NON-INVASIVE PROCEDURE
7.4 CHALLENGES
7.4.1 SIDE EFFECTS FOUND DURING LAM TREATMENT
7.4.2 PATIENT COMPLIANCE DURING THE TREATMENT OF LAM
8 IMPACT OF COVID-19 ON EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.1 ANALYSIS ON IMPACT OF COVID-19 ON LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.2 IMPACT ON PRICE OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.3 IMPACT ON DEMAND OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.4 IMPACT ON SUPPLY CHAIN OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.5 STRATEGIC DECISIONS BY MANUFACTURERS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.6 CONCLUSION
9 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 TUBEROUS SCLEROSIS COMPLEX LAM
9.3 SPORADIC LAM
10 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE
10.1 OVERVIEW
10.2 TREATMENT
10.2.1 MEDICATION
10.2.2 MTOR INHIBITORS
10.2.3 SIROLIMUS/ RAPAMYCIN
10.2.4 EVEROLIMUS
10.2.5 OTHERS
10.2.6 BRONCHODILATORS
10.2.7 ALBUTEROL
10.2.8 SALMETEROL
10.2.9 GLYCOPYRROLATE
10.2.10 OTHERS
10.2.11 OXYGEN THERAPY
10.2.12 LUNG TRANSPLANTATION
10.2.13 BILATERAL LUNG TRANSPLANTATION (BLT)
10.2.14 SINGLE-LUNG TRANSPLANTATION (SLT)
10.3 DIAGNOSIS
10.3.1 IMAGING TEST
10.3.2 CHEST X-RAYS
10.3.3 CHEST CT SCANS
10.3.4 MRI OF ABDOMEN
10.3.5 OTHERS
10.3.6 LUNG FUNCTION TEST
10.3.7 BLOOD TEST (VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D))
10.3.8 LUNG BIOPSY
10.3.9 VIDEO-ASSISTED THORASCOPIC LUNG BIOPSY
10.3.10 TRANSBRONCHIAL LUNG BIOPSY
10.3.11 OTHERS
10.3.12 OTHERS
11 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS
11.1 OVERVIEW
11.2 PNEUMOTHORAX
11.3 PLEURAL EFFUSIONS
11.4 KIDNEY TUMOR
11.5 CHYLOTHORAX
11.6 SWELLING & FLUID BUILD-UP
11.7 OTHERS
12 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLET
12.2.2 CAPSULES
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
13 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 DIAGNOSTIC CENTER
13.5 HOME HEALTHCARE
13.6 OTHERS
14 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACIES
14.4 RETAIL PHARMACIES
14.5 ONLINE PHARMACIES
14.6 OTHERS
15 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION
15.1 OVERVIEW
15.2 EUROPE
15.2.1 GERMANY
15.2.2 FRANCE
15.2.3 U.K.
15.2.4 HUNGARY
15.2.5 LITHUANIA
15.2.6 AUSTRIA
15.2.7 IRELAND
15.2.8 NORWAY
15.2.9 POLAND
15.2.10 ITALY
15.2.11 SPAIN
15.2.12 RUSSIA
15.2.13 TURKEY
15.2.14 NETHERLANDS
15.2.15 SWITZERLAND
15.2.16 REST OF EUROPE
16 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 COMPANY PROFILE
17.1 TERUMO CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 CAREDX, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 PFIZER INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 NOVARTIS AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 APOTEX INC
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 AMNEAL PHARMACEUTICALS LLC
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 HIKMA PHARMACEUTICALS PLC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 HERSILL
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 HOME OXYGEN COMPANY
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 INTAS PHARMACEUTICALS, LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 INOGEN INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 MORGAN SCIENTIFIC
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PULMONE ADVANCED MEDICAL DEVICES
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 PARAGONIX TECHNOLOGIES, INC
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 DR REDDY’S LABORATORIES LTD.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 SANDOR
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD)
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 TRANSMEDICS GROUP INC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 TAJ PHARMACEUTICALS LTD
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 XVIVO
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: PIPELINE ANALYSIS
TABLE 2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 EUROPE TUBEROUS SCLEROSIS COMPLEX LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 EUROPE SPORADIC LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE PNEUMOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE PLEURAL EFFUSIONS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE KIDNEY TUMOR IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE CHYLOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE SWELLING & FLUID BUILD-UP IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 26 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 EUROPE HOSPITALS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE SPECIALTY CLINICS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE DIAGNOSTIC CENTER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE HOME HEALTHCARE IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 35 EUROPE DIRECT TENDER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE HOSPITAL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE RETAIL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE ONLINE PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 42 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 43 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 53 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 59 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 GERMANY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 GERMANY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 GERMANY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 GERMANY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 GERMANY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 GERMANY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 GERMANY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 GERMANY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 69 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 GERMANY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 75 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 FRANCE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 FRANCE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 FRANCE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 FRANCE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 FRANCE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 FRANCE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 FRANCE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 FRANCE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 85 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 86 FRANCE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 87 FRANCE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 88 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 89 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 90 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.K. TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.K. MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.K. MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 U.K. BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 U.K. LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 U.K. DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 U.K. IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 U.K. LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 101 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 102 U.K. ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 103 U.K. PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 104 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 105 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 106 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 HUNGARY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 HUNGARY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 HUNGARY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 HUNGARY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 HUNGARY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 HUNGARY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 HUNGARY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 HUNGARY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 117 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 HUNGARY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 HUNGARY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 121 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 122 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 123 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 LITHUANIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 LITHUANIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 LITHUANIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 LITHUANIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 LITHUANIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 LITHUANIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 LITHUANIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 LITHUANIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 133 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 134 LITHUANIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 135 LITHUANIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 136 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 138 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 139 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 AUSTRIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 AUSTRIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 143 AUSTRIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 149 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 AUSTRIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 AUSTRIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 155 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 IRELAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 IRELAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 IRELAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 IRELAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 IRELAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 161 IRELAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 162 IRELAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 163 IRELAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 164 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 165 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 IRELAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 IRELAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 168 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 171 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 NORWAY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 NORWAY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 NORWAY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 NORWAY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 NORWAY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 NORWAY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 NORWAY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 NORWAY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 181 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 NORWAY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 NORWAY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 185 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 186 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 187 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 188 POLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 POLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 POLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 POLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 POLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 POLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 POLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 POLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 197 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 198 POLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 199 POLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 201 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 202 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 203 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 ITALY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 205 ITALY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 206 ITALY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 207 ITALY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 208 ITALY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 209 ITALY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 210 ITALY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 211 ITALY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 212 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 213 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 214 ITALY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 215 ITALY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 216 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 217 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 218 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 219 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 SPAIN TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 SPAIN MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 SPAIN MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 SPAIN BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 SPAIN LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 SPAIN DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 SPAIN IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 SPAIN LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 229 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 SPAIN ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 SPAIN PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 232 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 233 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 234 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 235 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 RUSSIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 RUSSIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 RUSSIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 RUSSIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 RUSSIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 RUSSIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 RUSSIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 RUSSIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 245 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 246 RUSSIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 247 RUSSIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 248 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 249 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 250 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 251 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 252 TURKEY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 253 TURKEY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 254 TURKEY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 255 TURKEY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 256 TURKEY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 257 TURKEY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 258 TURKEY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 TURKEY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 261 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 262 TURKEY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 263 TURKEY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 264 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 265 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 266 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 267 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 NETHERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 NETHERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 NETHERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 NETHERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 NETHERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 NETHERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 274 NETHERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 275 NETHERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 276 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 277 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 278 NETHERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 279 NETHERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 280 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 281 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 282 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 283 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 SWITZERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 SWITZERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 SWITZERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 SWITZERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 SWITZERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 SWITZERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 SWITZERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 SWITZERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 293 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 294 SWITZERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 295 SWITZERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 296 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 297 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 298 REST OF EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: MARKET INDICATION COVERAGE GRID
FIGURE 10 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC CYSTIC LUNG DISORDER , RISE IN CLINICAL TRIALS AND PRESENCE OF HEALTHCARE REIMBURSEMENT IS EXPECTED TO DRIVE THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKETIN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 DISEASE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
FIGURE 15 PREVALENCE OF CHRONIC PULMONARY (LUNG) CYSTS, WHICH INCREASES WITH AGE
FIGURE 16 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISORDER , HIGHER IN FEMALES
FIGURE 17 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE, 2020
FIGURE 18 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY TYPE, 2020
FIGURE 19 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COMPLICATIONS, 2020
FIGURE 20 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 21 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY END USER, 2020
FIGURE 22 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 23 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 24 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020)
FIGURE 25 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2021 & 2028)
FIGURE 26 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020 & 2028)
FIGURE 27 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 28 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 29 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020)
FIGURE 30 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 31 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 32 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 33 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
